Acute onset and worsening of diabetes concurrent with administration of statins

被引:24
作者
Ohmura, C [1 ]
Watada, H [1 ]
Hirose, T [1 ]
Tanaka, Y [1 ]
Kawamori, R [1 ]
机构
[1] Juntendo Univ, Sch Med, Dept Med Metab & Endocrinol, Bunkyo Ku, Tokyo 1138421, Japan
关键词
atorvastatin; pravastatin; HMG-CoA reductase inhibitor; hyperlipidemia; type; 2; diabetes;
D O I
10.1507/endocrj.52.369
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
We report a patient in whom the administration of HMG CoA reductase inhibitors (statins) might have triggered the onset and worsening of diabetes. The patient was a 48-year-old Japanese man who underwent annual medical examination but had never been told of hyperglycemia. Four months after the commencement of atorvastatin (10 mg/day) treatment, a diagnosis of diabetes mellitus was made from his typical symptoms of hyperglycemia, postprandial plasma glucose level of 29.8 mmol/l and HbA(1c) of 11.5%. After 2 months of insulin therapy and 3 months after the cessation of atorvastatin, almost complete resolution of diabetes was observed. During the subsequent 3 months, diet therapy alone was sufficient to control blood glucose level. Then, we prescribed pravastatin (20 mg/day). During the subsequent 3 months, HbA(1c) was gradually increased. However, after discontinuation of pravastatin, HbA(1c) was gradually decreased. In the general population, statin does not seem to have critical adverse effects on glucose tolerance, but it may uncommonly modify the natural course of the development of diabetes in certain patients.
引用
收藏
页码:369 / 372
页数:4
相关论文
共 12 条
[1]   Inhibition of isoprenoid biosynthesis causes insulin resistance in 3T3-L1 adipocytes [J].
Chamberlain, LH .
FEBS LETTERS, 2001, 507 (03) :357-361
[2]   Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial [J].
Colhoun, HM ;
Betteridge, DJ ;
Durrington, PN ;
Hitman, GA ;
Neil, HAW ;
Livingstone, SJ ;
Thomason, MJ ;
Mackness, MI ;
Charlton-Menys, V ;
Fuller, JH .
LANCET, 2004, 364 (9435) :685-696
[3]   RELATIONSHIP BETWEEN MEVALONATE PATHWAY AND ARTERIAL MYOCYTE PROLIFERATION - IN-VITRO STUDIES WITH INHIBITORS OF HMG-COA REDUCTASE [J].
CORSINI, A ;
MAZZOTTI, M ;
RAITERI, M ;
SOMA, MR ;
GABBIANI, G ;
FUMAGALLI, R ;
PAOLETTI, R .
ATHEROSCLEROSIS, 1993, 101 (01) :117-125
[4]  
Kearney D, 1999, J AM COLL CARDIOL, V33, P1305
[5]   HMG-CoA reductase inhibition:: Anti-inflammatory effects beyond lipid lowering? [J].
März, W ;
Wieland, H .
HERZ, 2000, 25 (02) :117-125
[6]  
PEDERSEN TR, 1994, LANCET, V344, P1383
[7]   The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels [J].
Sacks, FM ;
Pfeffer, MA ;
Moye, LA ;
Rouleau, JL ;
Rutherford, JD ;
Cole, TG ;
Brown, L ;
Warnica, JW ;
Arnold, JMO ;
Wun, CC ;
Davis, BR ;
Braunwald, E .
NEW ENGLAND JOURNAL OF MEDICINE, 1996, 335 (14) :1001-1009
[8]   Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA):: a multicentre randomised controlled trial [J].
Sever, PS ;
Dahlöf, B ;
Poulter, NR ;
Wedel, H ;
Beevers, G ;
Caulfield, M ;
Collins, R ;
Kjeldsen, SE ;
Kristinsson, A ;
McInnes, GT ;
Mehlsen, J ;
Nieminen, M ;
O'Brien, E ;
Östergren, J .
LANCET, 2003, 361 (9364) :1149-1158
[9]   PREVENTION OF CORONARY HEART-DISEASE WITH PRAVASTATIN IN MEN WITH HYPERCHOLESTEROLEMIA [J].
SHEPHERD, J ;
COBBE, SM ;
FORD, I ;
ISLES, CG ;
LORIMER, AR ;
MACFARLANE, PW ;
MCKILLOP, JH ;
PACKARD, CJ .
NEW ENGLAND JOURNAL OF MEDICINE, 1995, 333 (20) :1301-1307
[10]   EFFICACY AND LONG-TERM ADVERSE EFFECT PATTERN OF LOVASTATIN [J].
TOBERT, JA .
AMERICAN JOURNAL OF CARDIOLOGY, 1988, 62 (15) :J28-J34